The year 2010 was an encouraging time for prostate cancer patients, as significant strides in research led to the FDA approval of two new agents, sipuleucel-T and cabazitaxel. Until recently, only ...

SAN FRANCISCO — The addition of cabazitaxel to neoadjuvant abiraterone acetate did not improve tumor response among men with high-risk prostate cancer, according to randomized phase 2 study ...

Findings: Cabazitaxel cytotoxicity and radiosensitization were dose dependent. Cabazitaxel added 24 h before radiation was the most lethal schedule. DNA content measurements by flow cytometry showed ...

Review the side-effects of Cabazitaxel as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...

Cabazitaxel was approved in the U.S. for second-line use in advanced hormone-refractory prostate cancer in men in 2010, and has been described as a major advance in chemotherapy for advanced ...

Cabazitaxel can increase survival time in men with metastatic prostate for whom further treatment with docetaxel is no longer an option. In contrast, due to a lack of data, an added benefit is not ...

“Cabazitaxel combined with abiraterone significantly prolonged PFS, improved PSA response, and delayed TTPP compared to abiraterone alone in patients previously treated with docetaxel for metastatic ...

Cabazitaxel is due to be licensed in Europe in the next few months then rationing body NICE will rule if NHS patients can use it. It was developed at the Institute of Cancer Research and The Royal ...

TROPIC is a phase 3 randomised open‑label multicentre trial that compared cabazitaxel with mitoxantrone in men with metastatic hormone‑relapsed prostate cancer. The trial recruited people whose ...

Cabazitaxel is more effective than androgen receptor-axis-targeted therapy (ARAT) for third-line treatment of metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting, even ...